Showing 1791-1800 of 3314 results for "".
- Johnson & Johnson Vision’s Investigational Antihistamine-Releasing Contact Lens Demonstrates Positive Phase 3 Resultshttps://modernod.com/news/johnson-johnson-visions-investigational-antihistamine-releasing-contact-lens-demonstrates-positive-phase-3-results/2476418/Johnson & Johnson Vision announced that results from two phase 3 clinical studies evaluating the company’s investigational antihistamine-releasing contact lens (etafilcon A with 0.019 mg ketotifen) were published in the journal Cornea. The results demonstrated that patients weari
- Visioneering Technologies Selects Corneal Lens Corporation NZ and Contact Lens Centre Australia to Distribute NaturalVue Brand Contact Lenses in ANZhttps://modernod.com/news/visioneering-technologies-selects-corneal-lens-corporation-nz-and-contact-lens-centre-australia-to-distribute-naturalvue-brand-contact-lenses-in-anz/2479825/Visioneering Technologies announced that it has signed an agreement with Corneal Lens Corporation (CLC) and its associated company Contact Lens Centre Australia (CLCA), making them authorized distributors of Visioneering’s NaturalVue (etafilcon A) Brand 1 Day Contact Lenses in New Zealand and Aus
- New Dates Set for Vision Expo East 2021https://modernod.com/news/new-dates-for-vision-expo-east-2021/2478371/The Vision Council and Reed Exhibitions, organizers of Vision Expo, announced that Vision Expo East 2021, originally scheduled to take place from March 18–21, will now take place May 25–28, 2021 (Education: May 25–28; Exhibition: May 26–28) at the Javits Center in New York City. The date change r
- Kala Pharmaceuticals Announces Financing from Athyrium Capital Management Totaling $110 Millionhttps://modernod.com/news/kala-pharmaceuticals-announces-financing-from-athyrium-capital-management-totaling-110-million/2479817/Kala Pharmaceuticals announced the closing of Kala’s $110 million credit facility with funds managed by Athyrium Capital Management LP, a healthcare focused investment firm. “We are pleased to be partnering with Athyrium and to have their support and confidence in Inveltys for the treatmen
- PulseSight Therapeutics Initiates Clinical Plan of PST-611 Transferrin Vectorized Therapy for Dry AMD/GAhttps://modernod.com/news/pulsesight-therapeutics-initiates-clinical-plan-of-pst-611-transferrin-vectorized-therapy-for-dry-amdga/2482615/PulseSight Therapeutics SAS announced it has submitted a clinical trial authorization (CTA) to Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM) for a phase 1 trial (PST-611-CT1) assessing the safety
- Mice Sent to Space on SpaceX Rocket as Part of Oculogenex Gene Therapy Studyhttps://modernod.com/news/gene-therapy-company-oculogenex-set-to-launch-on-spacex-crs-30-today/2482175/Today’s scheduled launch of NASA’s SpaceX CRS-30 mission will carry more than 40 science payloads to the International Space Station for a new round of microgravity research. SpaceX CRS-30 is scheduled to launch today at 4:55 ET. The mission will include Oculogene
- Prevent Blindness to Host “World Sight Day” Congressional Briefing and Free Vision Screening on Capitol Hillhttps://modernod.com/news/prevent-blindness-to-host-world-sight-day-congressional-briefing-and-free-vision-screening-on-capitol-hill/2481872/Nonprofit Prevent Blindness will be hosting a Congressional Briefing and free vision screening on October 12 from 10 am to 2 pm ET. The event, with support from the Prevention of Blindness Society of Metropolitan Washington, is part of this year’s
- Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hemodynamics and Retinal Cell Physiologyhttps://modernod.com/news/nicox-announces-publication-of-ncx-470-results-demonstrating-improvements-to-ocular-hemodynamics-and-retinal-cell-physiology-1/2480951/Nicox SA announced that the results from studies on the beneficial effects of NCX 470 in a nonclinical model of endothelin-1 (ET-1)-induced ischemia/reperfusion damage of the optic nerve head and retina have been published online in the peer-reviewed Journal of Ocular Pharmacology and Therape
- Visus Therapeutics to Host Its First Capital Markets Day Tomorrowhttps://modernod.com/news/visus-therapeutics-to-host-its-first-capital-markets-day-tomorrow/2479476/Visus Therapeutics will host its first Capital Markets Day for investors, analysts, and media tomorrow, August 31, 2021, from 10 am to 2 pm ET at Convene, 530 Fifth Avenue at 45th Street in New York City. During the Capital Markets Day, Ben Bergo, co-founder and chief executive
- Live Webcast: COVID-19 Impact on Retina Practiceshttps://modernod.com/news/live-webcast-covid-19-impact-on-retina-practices/2477468/Bryn Mawr Communications (BMC) will host a live video webcast of its New Retina Radio podcast on Friday at 12 pm ET. The webcast, “How Retina Doctors Are Altering Their Treatments During the COVID-19 Crisis, and How They Can Anticipate What’s Next,” will be hosted by John W. Kitchens, MD. Panelis